

Dr. John Boone on how Izotropic's CT technology will outperform mammography for more accurate breast cancer detection

"We believe, based upon our computer simulation, that breast CT system will outperform mammography, for instance for a 4 mm lesion, a pretty small tumor, by the order of 40%. We are very excited about the increase in cancer detection performance that breast CT will provide." States Dr. John Boone, Principal Founder, Director of Izotropic Corporation (CSE: IZO) and the 2019 William D. Coolidge Award Recipient in an interview with InvestorIntel's Peter Clausi.

Dr. Boone went on to explain that Izotropic's breast CT technology is comfortable for patients as it does not involve painful breast compression and produces true 3-D images of breasts at very high resolution. Dr. Boone added that the technology has the potential to substantially reduce false-negative or false-positive breast biopsies thereby reducing the stress on the patient and also reducing the cost for the medical system.

To access the complete interview, [click here](#)

Disclaimer: Izotropic Corporation is an advertorial member of InvestorIntel Corp.